{
  "docId": "019de071-b74f-770c-80cd-22f6f746fca1",
  "docSlug": "da6e8db4dad70fc7ff4e589a15b2ab41",
  "documentTitle": "BioNTech | Results Presentation Deck | 40 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 40,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-b74f-770c-80cd-22f6f746fca1/39",
  "deckHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1",
  "deckJsonHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1.json",
  "deckAnchorHref": "/decks/019de071-b74f-770c-80cd-22f6f746fca1#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.05,
        "y": 0.425
      },
      "kind": "list",
      "text": "15 Oncology product candidates in 19 ongoing clinical trials; 3 Phase 2 trials started in 2021; 5 First-in-human trial starts in 2021; 6 program updates at SITC; Expansion into new class of Precision Antibacterials",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58a37d27-29a9-496d-a8a7-2e75ee7dcc32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.67,
        "y": 0.425
      },
      "kind": "list",
      "text": "Continued expansion in U.S. with acquisition of cGMP Kite Cell Therapy manufacturing facility; Planning to establish Southeast Asia headquarters in Singapore; BioNTech R&D Austria established through PhagoMed acquisition",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a00af174-036e-40d7-88a9-82d26d67f9eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.36,
        "y": 0.425
      },
      "kind": "list",
      "text": "Expansion of team to more than 2,800 professionals globally; Significant investments in digital; Further scale-up of Marburg mRNA manufacturing site; Planning further mRNA manufacturing sites in Africa and Singapore",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cebe31b3-846d-4b1e-8dd4-17b82be9a73b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.82
      },
      "kind": "paragraph",
      "text": "Building long-term value for patients, investors and and society as we advance our vision of harnessing the immune system’s full potential to fight human disease",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7e5027a9-8198-4ceb-adb0-97b6c3e84e3c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Poised to Accelerate Our Transformation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f301dece-0546-4353-b3a1-2ce97c053d9a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "2f39b936-d819-4cb5-8cf8-14501f21eda6",
      "evidence": "list/bullet: Continued expansion in U.S. with acquisition of cGMP Kite Cell Therapy manufacturing facility; Planning to establish Southeast Asia headquarters in Singapore; BioNTech R&D Austria established through PhagoMe",
      "confidence": 0.8
    },
    {
      "name": "Storytelling: the closing ask",
      "slug": "closing-ask",
      "agent": "storyteller",
      "layer": "slide",
      "matchId": "8fb4cc41-0cca-4952-bef8-0897d96b5518",
      "evidence": "Building long-term value for patients, investors and and society as we advance our vision of harnessing the immune system’s full potential to fight human disease",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 40,
      "from": 21,
      "beatId": "86ee922b-3b38-407a-91d0-e5fba14e6389",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The presentation concludes with financial results, outlook, and future plans",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}